Docetaxel, derived from the yew tree, belongs to the taxane family of medications. It works by disrupting the normal function of microtubules, thereby stopping cell division. Docetaxel is used in the treatment of ovarian, breast, esophageal, gastric, prostate, lung, and head and neck cancers. Common side effects include hair loss, low blood cell counts, peripheral neuropathy, vomiting, and muscle pain. Auricular chondritis with ear deformity has not been reported previously as a side effect of docetaxel. In this paper, we present the case of a 64-year-old male patient with chondritis accompanied by ear deformity that developed due to docetaxel–carboplatin chemotherapy for non-small cell lung cancer.
EisenhauerEAVermorkenJB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs1998; 55: 5–30.
2.
DiazJFAndreuJM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere—reversibility, ligand stoichiometry, and competition. Biochemistry1993; 32: 2747–2755.
3.
JordanMATosoRJThrowerDet al.Mechanism of mitotic block and inhibition of cell-proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A1993; 90: 9552–9556.
4.
SparanoJA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer2000; 1: 32–40. ; discussion 41–32.
5.
ClarkeSJRivoryLP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet1999; 36: 99–114.
6.
MiyawakiYNakajimaYKawadaKet al.Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Dis Esophagus2017; 30: 1–8. DOI: 10.1111/dote.12485.
7.
MillwardMJBoyerMJLehnertMet al.Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol2003; 14: 449–454.
8.
MatikasAGeorgouliasVKotsakisA. The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. Expert Rev Respir Med2016; 10: 1229–1241.
9.
HoMYMackeyJR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res2014; 6: 253–259.
10.
Naidu SugnanamKKTurnerNHO'HaganS. Docetaxel-related toxic optic neuropathy in management of prostate adenocarcinoma. Clin Genitourin Cancer2017; 15: e115–e118.
11.
ArshadFBhatTSLoneAR. Docetaxel induced Lyell's syndrome: a rare life threatening cause of dermatitis medicamentosas. J Cancer Res Ther2014; 10: 742–744.
12.
HughesBGStuart-HarrisR. Docetaxel-induced myositis: report of a novel side-effect. Intern Med J2005; 35: 369–370.
ChoongNWMauerAMHarafDJet al.Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small lung cancer. J Thorac Oncol2008; 9: 1003–1011.
16.
BrantAJRucksteinMJCummings Otolaryngology – Head and Neck Surgery. Infections of the external ear. In: FlintPWHaugheyBHLundVJet al.(eds). Cummings otolaryngology20156th ed. Elsevier Saunders, pp. 2115–2122. .
17.
Al-ThenayanEMaghfoorI. Complications of malignancy: case 1. Systemic tumor embolism from lung cancer at presentation. J Clin Oncol2004; 22: 372–373.
18.
TakedaMKobayashiTMarumoSet al.Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: a case report. Mol Clin Oncol2013; 1: 851–852.
19.
LeonardGDZujewskiJA. Docetaxel-related skin, nail, and vascular toxicity. Ann Pharmacother2003; 37: 148.
20.
TanTHStevensonBYipD. Docetaxel-induced nasal septal perforation. Intern Med J2006; 36: 471–472.
21.
RosettiMZoliWTeseiAet al.Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. J Cell Physiol2007; 212: 710–716.
